{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:14:13Z","timestamp":1793708053713,"version":"4.6.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":1584,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>No evidence-based tools exist to enhance precision in the selection of patient-specific optimal treatment durations to study in tuberculosis clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To develop risk stratification tools that assign patients with tuberculosis into risk groups of unfavorable outcome and inform selection of optimal treatment duration for each patient strata to study in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publicly available data from four phase 3 trials, each evaluating treatment duration shortening from 6 to 4 months, were used to develop parametric time-to-event models that describe unfavorable outcomes. Regimen, baseline, and on-treatment characteristics were evaluated as predictors of outcomes. Exact regression coefficients of predictors were used to assign risk groups and predict optimal treatment durations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>The parametric model had an area under the receiver operating characteristic curve of 0.72. A six-item risk score (HIV status, smear grade, sex, cavitary disease status, body mass index, and Month 2 culture status) successfully grouped participants into low (1,060\/3,791; 28%), moderate (1,740\/3,791; 46%), and high (991\/3,791; 26%) risk, requiring treatment durations of 4, 6, and greater than 6 months, respectively, to reach a target cure rate of 93% when receiving standard-dose rifamycin-containing regimens. With current one-duration-fits-all approaches, high-risk groups have a 3.7-fold (95% confidence interval, 2.7\u20135.1) and 2.4-fold (1.9\u20132.9) higher hazard risk of unfavorable outcomes compared with low- and moderate-risk groups, respectively. Four-month regimens were noninferior to the standard 6-month regimen in the low-risk group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our model discrimination was modest but consistent with current models of unfavorable outcomes. Our results showed that stratified medicine approaches are feasible and may achieve high cure rates in all patients with tuberculosis. An interactive risk stratification tool is provided to facilitate decision-making in the regimen development pathway.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202101-0117oc","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T10:46:46Z","timestamp":1628074006000},"page":"1086-1096","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":48,"title":["Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials"],"prefix":"10.1093","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-3012","authenticated-orcid":false,"given":"Marjorie Z.","family":"Imperial","sequence":"first","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences"},{"name":"University of California, San Francisco, Center for Tuberculosis, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7024","authenticated-orcid":false,"given":"Patrick P. J.","family":"Phillips","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Center for Tuberculosis, and"},{"name":"Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-1311","authenticated-orcid":false,"given":"Payam","family":"Nahid","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Center for Tuberculosis, and"},{"name":"Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5579","authenticated-orcid":false,"given":"Radojka M.","family":"Savic","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences"},{"name":"University of California, San Francisco, Center for Tuberculosis, and"},{"name":"Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"2026030321581300800_bib1","doi-asserted-by":"crossref","first-page":"e1002769","DOI":"10.1371\/journal.pmed.1002769","article-title":"Advances in clinical trial design for development of new TB treatments: a call for innovation","volume":"16","author":"Lienhardt","year":"2019","journal-title":"PLoS Med"},{"key":"2026030321581300800_bib2","author":"World Health Organization","year":"2016"},{"key":"2026030321581300800_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nm0307-290","article-title":"Challenges in tuberculosis drug research and development","volume":"13","author":"Ginsberg","year":"2007","journal-title":"Nat Med"},{"key":"2026030321581300800_bib4","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026030321581300800_bib5","author":"World Health Organization","year":"2017"},{"key":"2026030321581300800_bib6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026030321581300800_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijid.2016.02.863","article-title":"TRUNCATE-TB: an innovative trial design for drug-sensitive tuberculosis","volume":"45","author":"Papineni","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2026030321581300800_bib8","author":"Imperial"},{"key":"2026030321581300800_bib9","article-title":"Predicting optimal treatment durations for tuberculosis patients: risk stratification algorithm and simulation tool","author":"Imperial","journal-title":"Presented at American Society for Clinical Pharmacology and Therapeutics Annual Meeting. March 2021"},{"key":"2026030321581300800_bib10","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N Engl J Med"},{"key":"2026030321581300800_bib11","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"2026030321581300800_bib12","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N Engl J Med"},{"key":"2026030321581300800_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1164\/rccm.200904-0536OC","article-title":"Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion","volume":"180","author":"Johnson","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321581300800_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/0-387-29150-4","volume-title":"Survival analysis: a self-learning text.","author":"Kleinbaum","year":"2005"},{"key":"2026030321581300800_bib15","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/sim.2174","article-title":"Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data","volume":"24","author":"Xie","year":"2005","journal-title":"Stat Med"},{"key":"2026030321581300800_bib16","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat Med"},{"key":"2026030321581300800_bib17","author":"World Health Organization","year":"2008"},{"key":"2026030321581300800_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0007-0971(81)90022-X","article-title":"Whither short-course chemotherapy?","volume":"75","author":"Fox","year":"1981","journal-title":"Br J Dis Chest"},{"key":"2026030321581300800_bib19","first-page":"e1002773","article-title":"Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: a mechanistic model and tool for regimen and dose optimization","volume-title":"PLOS Med","author":"Strydom","year":"2019"},{"key":"2026030321581300800_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis: a randomized, dose-ranging trial","volume":"191","author":"Dorman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321581300800_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and safety of high-dose rifampin in pulmonary tuberculosis: a randomized controlled trial","volume":"198","author":"Vel\u00e1squez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321581300800_bib22","first-page":"e0125403","article-title":"Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update","volume-title":"PLoS One","author":"Wallis","year":"2015"},{"key":"2026030321581300800_bib23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cts.12472","article-title":"New paradigm for translational modeling to predict long-term tuberculosis treatment response","volume":"10","author":"Bartelink","year":"2017","journal-title":"Clin Transl Sci"},{"key":"2026030321581300800_bib24","author":"World Health Organization","year":"2019"},{"key":"2026030321581300800_bib25","author":"European Medicines Agency","year":"2020"},{"key":"2026030321581300800_bib26","author":"European Medicines Agency","year":"1998"},{"key":"2026030321581300800_bib27","first-page":"e63840","article-title":"An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse","volume-title":"PLoS One","author":"Phillips","year":"2013"},{"key":"2026030321581300800_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12916-016-0565-y","article-title":"Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials","volume":"14","author":"Phillips","year":"2016","journal-title":"BMC Med"},{"key":"2026030321581300800_bib29","doi-asserted-by":"crossref","first-page":"e0197880","DOI":"10.1371\/journal.pone.0197880","article-title":"Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis","volume":"13","author":"Alene","year":"2018","journal-title":"PLoS One"},{"key":"2026030321581300800_bib30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1473-3099(10)70071-2","article-title":"Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis","volume":"10","author":"Horne","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2026030321581300800_bib31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/17476348.2016.1166960","article-title":"Assessment of treatment response in tuberculosis","volume":"10","author":"Rockwood","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"2026030321581300800_bib32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1473-3099(13)70034-3","article-title":"Tuberculosis biomarkers discovery: developments, needs, and challenges","volume":"13","author":"Wallis","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2026030321581300800_bib33","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1164\/rccm.201103-0536OC","article-title":"A multisite assessment of the quantitative capabilities of the Xpert MTB\/RIF assay","volume":"184","author":"Blakemore","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321581300800_bib34","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1164\/rccm.201312-2140OC","article-title":"Xpert MTB\/RIF as a measure of sputum bacillary burden: variation by HIV status and immunosuppression","volume":"189","author":"Hanrahan","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321581300800_bib35","first-page":"e0160062","article-title":"Bacterial loads measured by the Xpert MTB\/RIF assay as markers of culture conversion and bacteriological cure in pulmonary TB","volume-title":"PLoS One","author":"Shenai","year":"2016"},{"key":"2026030321581300800_bib36","first-page":"e1002780","article-title":"Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: analytic validation and evaluation in two cohorts","volume-title":"PLoS Med","author":"Kawasaki","year":"2019"},{"key":"2026030321581300800_bib37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(13)70119-X","article-title":"Assessment of the sensitivity and specificity of Xpert MTB\/RIF assay as an early sputum biomarker of response to tuberculosis treatment","volume":"1","author":"Friedrich","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026030321581300800_bib38","author":"World Health Organization","year":"2021"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/204\/9\/1086\/67012420\/ajrccm_204_9_1086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/204\/9\/1086\/67012420\/ajrccm_204_9_1086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:58:23Z","timestamp":1772593103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/204\/9\/1086\/8492281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202101-0117oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"2021-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}